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ardiac Resynchronization With
equential Biventricular Pacing for the
reatment of Moderate-to-Severe Heart Failure
ngel R. León, MD,* William T. Abraham, MD,†‡ Susan Brozena, MD,¶ James P. Daubert, MD,§
estby G. Fisher, MD,† John C. Gurley, MD,† Chang Seng Liang, MD,§ George Wong, MD,#
or the InSync III Clinical Study Investigators
tlanta, Georgia; Lexington, Kentucky; Columbus, Ohio; Rochester, New York; Evanston, Illinois;
hiladelphia, Pennsylvania; and Peoria, Arizona
OBJECTIVES The InSync III study evaluated sequential cardiac resynchronization therapy (CRT) in patients
with moderate-to-severe heart failure and prolonged QRS.
BACKGROUND Simultaneous CRT improves hemodynamic and clinical performance in patients with moderate-
to-severe heart failure (HF) and a wide QRS. Recent evidence suggests that sequentially
stimulating the ventricles might provide additional benefit.
METHODS This multicenter, prospective, nonrandomized, six-month trial enrolled a total of 422 patients
to determine the effectiveness of sequential CRT in patients with New York Heart
Association (NYHA) functional class III or IV HF and a prolonged QRS. The study
evaluated: whether patients receiving sequential CRT for six months experienced improve-
ment in 6-min hall walk (6MHW) distance, NYHA functional class, and quality of life
(QoL) over control group patients from the reported Multicenter InSync Randomized
Clinical Evaluation (MIRACLE) trial; whether sequential CRT increased stroke volume
compared to simultaneous CRT; and whether an increase in stroke volume translated into
greater clinical improvements compared to patients receiving simultaneous CRT.
RESULTS InSync III patients experienced greater improvement in 6MHW, NYHA functional class,
and QoL at six months compared to control (all p  0.0001). Optimization of the sequential
pacing increased (median 7.3%) stroke volume in 77% of patients. No additional improve-
ment in NYHA functional class or QoL was seen compared to the simultaneous CRT group;
however, InSync III patients demonstrated greater exercise capacity.
CONCLUSIONS Sequential CRT provided most patients with a modest increase in stroke volume above that
achieved during simultaneous CRT. Patients receiving sequential CRT had improved exercise
capacity, but no change in functional status or QoL. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.0322298–304) © 2005 by the American College of Cardiology Foundation
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snterventricular (V-V) conduction delay commonly occurs
n patients with chronic systolic heart failure (HF) and
roduces dyssynchronous ventricular contraction that fur-
her impairs cardiac function (1–4). Recent studies demon-
trated that cardiac resynchronization therapy (CRT) uti-
izing simultaneous biventricular (Bi-V) pacing improves
he hemodynamic and clinical performance of patients with
oderate-to-severe HF and a V-V conduction delay by
orrecting dyssynchronous ventricular contraction (5–13).
The degree and mechanical manifestations of ventricular
yssynchrony vary widely among patients with HF and a
-V conduction delay (14). Sequential Bi-V stimulation
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his study was supported by Medtronic Inc., Minneapolis, Minnesota. Drs. Leon,
braham, Brozena, Daubert, Fisher, and Gurley have been speakers for Medtronic
nc. Drs. Leon, Abraham, Daubert, and Fisher are consultants to Medtronic Inc.e
Manuscript received August 26, 2004; revised manuscript received December 10,
004, accepted December 14, 2004.ses a programmable V-V pacing interval, which can be
ndividually tailored to potentially maximize electromechan-
cal resynchronization. Small, short-term studies demon-
trated further improvement in systolic and diastolic func-
ion during sequential Bi-V CRT (12,14–16). The present
tudy more thoroughly evaluates the clinical and hemody-
amic effects of sequential Bi-V pacing using the InSync III
RT device (17).
ETHODS
he InSync III clinical study used a multicenter, prospec-
ive, nonrandomized design to evaluate the clinical effec-
iveness of sequential Bi-V CRT. The study compared its
ffectiveness to the Multicenter InSync Randomized Clin-
cal Evaluation (MIRACLE) control group that received
ptimal pharmacological therapy alone. Additional post-
oc analysis compared the effectiveness of sequential CRT
o simultaneous CRT provided to the MIRACLE treat-
ent group (5). The MIRACLE study utilized many of the
ame investigational centers and had the same inclusion and
xclusion criteria, implant procedure, therapy delivery scheme,
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December 20, 2005:2298–304 Efficacy of Sequential CRTnd primary end point analysis as the present trial (5). Both
tudies enrolled patients with New York Heart Association
NYHA) functional class III or IV HF, a left ventricular
LV) ejection fraction 35%, a QRS duration 130 ms,
nd an LV end-diastolic diameter of 55 mm. Before
ither study entry, all candidates must have received opti-
al and stable pharmacological therapy, including an
ngiotensin-converting enzyme inhibitor or an angiotensin
I receptor blocker and a beta-blocker in most patients. The
rotocol discouraged initiation of beta-blockade during the
ix-month evaluation period. Patients were excluded from
he study if they had any of the following: an indication for
mplantable cardioverter-defibrillator or pacemaker, the
resence of a previously implanted pacing system or an
ndication/contraindication to a standard pacing system,
ersistent atrial arrhythmias, a baseline 6-min hall walk
6MHW) distance 450 m, unstable angina, acute myo-
ardial infarction, coronary artery revascularization within
hree months before enrollment, changes in beta-blocker
oses within three months before enrollment, intermittent
notropic drug therapy (more than two outpatient dose
nfusions per week), severe primary pulmonary disease, or
rimary valvular disease.
The investigational review board at each participating
nstitution reviewed and approved the study protocol and
atient consent form; all enrolled patients provided written,
nformed consent.
evice description. The InSync III Model 8042 pulse
enerator (Medtronic Inc. Minneapolis, Minnesota) pro-
ides atrial-synchronous, sequential Bi-V stimulation for
RT. The device can stimulate either ventricle first, with a
rogrammable interval between the first and second ven-
ricular pacing output ranging between 4 and 80 ms. The
ominal, or simultaneous, V-V setting uses a 4-ms LV-
ight ventricle (RV) sequence. The device senses intrinsic
entricular activity through the RV lead, LV lead, or a
ombination of both (RV cathode to LV cathode). Incor-
oration of a V-V refractory period prevents double-counting
f a single ventricular depolarization sensed in both ventricles.
tudy protocol. Patients who met the entry criteria and
rovided signed consent underwent the following baseline
Abbreviations and Acronyms
Bi-V  biventricular
CRT  cardiac resynchronization therapy
HF  heart failure
LV  left ventricle/ventricular
MIRACLE  Multicenter InSync Randomized Clinical
Evaluation trial
NYHA  New York Heart Association
PHD  prehospital discharge
QoL  quality of life
RV  right ventricle/ventricular
V-V  interventricular
6MHW  6-min hall walkssessment: determination of NYHA functional class, 12- Vead electrocardiogram, 6MHW test, and quality of life
QoL) survey using the Minnesota Living with Heart
ailure Questionnaire. Echocardiographic determination of
he LV ejection fraction and LV end-diastolic diameter had
o be performed within 12 months before the baseline
valuation.
All patients underwent an implant attempt utilizing stan-
ard right atrial and RV pacing leads and one of three LV
ransvenous leads (Models 2187, 2188, or 4193, Medtronic,
nc.) positioned within a cardiac vein. Patients with a
uccessful implant received active CRT for the six-month
uration of the trial. The designated pacing mode, VDD,
rovided atrial-synchronous Bi-V pacing at either nominal
r sequential Bi-V settings without the confounding effect
f sensor-driven atrial pacing on cardiac performance.
All patients with a successful implant underwent full
nterrogation of the device, reassessment of QoL, follow-up
MHW test, estimation of NYHA functional class, and
onitoring of the background drug regimen before hospital
ischarge (PHD) and at one, three, and six months after
mplant. At PHD, three and six-month echocardiographic
valuation included optimization of the atrioventricular and
-V stimulation intervals. Echocardiography-Doppler in-
errogation first determined the optimal atrioventricular
nterval that maximizes transmitral filling using the Ritter
ethod (18). We kept the right-atrium-to-LV interval
onstant at the optimal setting while varying the LV-RV
nterval in random sequence 80 (RV first) to 80 ms (LV
rst) to identify the V-V offset producing the greatest LV
troke volume. Echocardiography-Doppler examination of
V outflow determined stroke volume at each V-V setting
s the product of the measured aortic velocity time integral
nd the LV outflow tract cross-sectional area determined by
wo-dimensional echocardiography. We defined the im-
rovement in stroke volume as the difference between the
troke volume at the optimal V-V setting and stroke volume
t the nominal, or simultaneous, V-V setting.
tatistical analysis. Evaluating the clinical effectiveness of
he InSync III CRT device and its V-V timing feature
erved as the primary objective of this study. The primary
linical efficacy end points for CRT included NYHA
unctional class, QoL, and 6MHW distance; the improve-
ent in stroke volume served as the primary end point in
nalyzing the effectiveness of the V-V timing feature.
For CRT therapy efficacy, changes from baseline to the
ix-month visit were calculated. The mean changes were then
ompared between the InSync III patients and the MIRA-
LE control group using two-sided, two-sample t tests. We
valuated all patients with valid end point scores in the
nalysis. Based on Hochberg’s multiple comparison proce-
ure (19), the study achieved its prespecified objective if the
ifferences in all three end points had a p value 0.05, if
wo had a p value 0.025, or if one had a p value 0.0167.
e estimated the median percent improvement of stroke
olume from the nominal to the optimal V-V setting. The
-V timing feature was considered effective if the median
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Efficacy of Sequential CRT December 20, 2005:2298–304mprovement exceeded 10% at all three time points (PHD,
hree months, and six months) using the sign test. We
onsidered a p value 0.05 as statistically significant.
ESULTS
atient disposition and implant data. Investigators and
oordinators enrolled 422 patients at 28 centers in the U.S.
etween November 30, 2000, and June 4, 2002. Table 1
isplays the baseline clinical characteristics of the patients
nrolled in the respective studies in the MIRACLE
rogram.
System implantation succeeded in 397 of 422 (94%) of
he enrolled patients. The majority of implants (387 of 422)
equired only one attempt. Nine patients received the CRT
evice on the second attempt, and one implant succeeded
fter a third attempt. The distribution of successfully im-
lanted LV leads consisted of 67% at the lateral region, 14%
t the anterior region, 14% at the posterior region, and 5%
t the apical region. The total implant procedure time
veraged 152.1 min (range: 54 to 450 min), and the time to
V lead placement averaged 20.3 min (range: 0 to 270 min).
atient follow-up experience ranged between 0.7 and 25.5
Table 1. InSync III and MIRACLE Control a
Characteristic
InSync III Treat
(6-Month Visi
(n  359)
Gender
Male 211 (58.8%
Female 148 (41.2%
Age (yrs) 65.8 (10.8)
Ejection fraction (%) 21.5 (6.9)
NYHA functional classification
III 329 (91.6%
IV 30 (8.4%)
QRS duration (ms) 163.9 (21.6)
LVEDD (mm) 68.4 (9.4)
Underlying heart disease
Ischemic 166 (46.2%
Nonischemic 193 (53.8%
Myocardial infarction 124 (34.5%
Beta-blocker usage 255 (71.0%
Atrial rhythm history
History of atrial arrhythmia 322 (89.7%
Normal sinus rhythm 37 (10.3%
Ventricular rhythm history
History of ventricular
arrhythmia
283 (78.8%
Normal sinus rhythm 76 (21.2%
Prior surgery 215 (59.9%
Coronary artery bypass 103 (28.7%
Angioplasty 46 (12.8%
Left bundle branch block 305 (85.0%
Values are either mean (SD) or n (%). *p values 0.05 betw
values 0.05 between InSync III treatment (sequential card
(simultaneous CRT). The p values were calculated from tw
chi-square test for categorical variables.
LVEDD  left ventricular end-diastolic diameter; MIR
NYHA  New York Heart Association.onths and averaged 13.9  6.0 months. fWe documented 41 perioperative (occurring either
uring implant or within seven days) system- or
rocedure-related complications in 37 patients, and 38
omplications in 36 patients during the postoperative
ix-month follow-up period (Table 2). Complications
lassified as “other” consisted of any event requiring
ntervention, as well as device reprogramming, including,
ut not exclusively, acidosis, nausea, acute respiratory
istress, peripheral intravenous infiltration, lead connec-
ion problem, etc.
verall clinical efficacy. Figures 1A to 1C compare the
linical effectiveness of CRT in the InSync III group to the
IRACLE control group and the MIRACLE CRT treat-
ent group at six months after implant; CRT significantly
mproved 6MHW distance, QoL, and NYHA functional
lassification in the InSync III population from baseline to
ix months (all p  0.0001). The Wilcoxon rank-sum test
roduced all p values 0.0001. Even after a regression
odel adjusted for differences in baseline patient character-
stics between the InSync III and MIRACLE control
roups (Table 1), CRT significantly improved each primary
nd point for the InSync III patients (p  0.0009 for
MHW; p  0.0049 for QoL; and p  0.0001 for NYHA
reatment Groups Demographic Comparison
MIRACLE Control
(6-Month Visits)
(n  207)
MIRACLE Treatment
(6-Month Visits)
(n  217)
142 (68.6%)* 145 (66.8%)
65 (31.4%) 72 (33.2%)
64.8 (11.4) 63.7 (10.5)
22.0 (6.2) 21.8 (6.2)
192 (92.8%) 198 (91.2%)
15 (7.2%) 19 (8.8%)
164.7 (20.4) 167.8 (20.7)†
68.3 (9.6) 69.8 (9.7)
119 (57.5%)* 110 (50.7%)
88 (42.5%) 107 (49.3%)
92 (44.4%)* 89 (41.0%)
118 (57.0%)* 137 (63.1%)†
182 (87.9%) 188 (86.6%)
25 (12.1%) 29 (13.4%)
163 (75.1%) 0.3014
54 (24.9%)
130 (59.9%) 0.9964
58 (26.7%) 0.6110
34 (15.7%) 0.3370
180 (82.9%) 0.5218
Sync III treatment and MIRACLE control at baseline; †p
ynchronization therapy [CRT]) and MIRACLE treatment
ple t tests for continuous variables and from the Pearson
E  Multisite InSync RAndomized CLinical Evaluation;nd T
ment
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December 20, 2005:2298–304 Efficacy of Sequential CRTn average of 61 m farther than they did at baseline and
eported a 22-point improvement in QoL score. In addi-
ion, 253 of 359 patients (70%) improved at least one class
n the NYHA scale.
ncremental benefit of sequential Bi-V pacing. The abil-
ty to vary the V-V interval increased stroke volume in 81%
f the InSync III patients at six months (Table 3). Stroke
olume improved (optimal vs. nominal V-V setting) by
.6% (median percentage) at PHD, 8.4% at three months,
nd 7.3% at six months. Sixty-four patients (17%) at PHD,
9 patients (14%) at three months, and 49 patients (14%) at
ix months experienced a 20% improvement in stroke
olume during sequential Bi-V pacing.
In the subset of patients who achieved maximum stroke
olume at a V-V setting other than nominal (LV stimula-
ion precedes RV by 4 ms) (Table 4), the median improve-
ents in stroke volume were 11.3%, 10.4%, and 9.8% at
HD, three, and six months, respectively.
Figure 2 illustrates the distribution of the optimal LV-RV
ettings at PHD, three, and six months. More than 75% of
atients at each assessment had an optimal LV-RV setting
etween 40 ms to 40 ms. The majority of patients had
n optimal V-V setting delivering LV stimulation first
55%, 54%, and 58% at the PHD, three, and six months
isits, respectively). The proportion of patients with a
ominal, or simultaneous, optimal V-V setting remained
airly stable over time (23%, 20%, and 19% at PHD, three,
nd six months, respectively). The proportion of patients
ith an optimal V-V setting delivering RV stimulation first
lso remained consistent at the three follow-up visits (23%,
6%, and 23%, respectively).
A post-hoc comparison of clinical efficacy end points
etween the InSync III and MIRACLE treatment groups
evealed no significant difference in the effect of optimized
equential and simultaneous CRT on NYHA functional
lass or QoL improvement. However, the InSync III group
Table 2. Patients With Complications During
Description Implant At
LV–lead-related* 5
RA–lead-related* 4
RV–lead-related* 1
Implant–tool-related* 8
Pocket-related (including infection) 2
Heart block 3
Junctional/VT/VF 3
CHF decompensation 1
Hemo/pneumothorax 3
Thrombosis N/A
Other† 11
Total patients‡ 37
*Includes atrial fibrillation, coronary sinus or cardiac vei
dislodgement, elevated threshold, failure to capture/exit bloc
acute respiratory distress (1), anemia (1), connector error
nocturnal dyspnea (1), peripheral intravenous infiltration (
acidosis (1), respiratory decompensation (1), and stroke/cereb
one complication.
CHF  congestive heart failure; LV  left ventricular
fibrillation; VT  ventricular tachycardia.xperienced a greater improvement in 6MHW from base- Bine to six months compared to the MIRACLE simulta-
eous CRT treatment group (Table 5, p values from
wo-sample t tests). The Wilcoxon rank-sum test produced
imilar results with p values of 0.0015, 0.1958, and 0.3364
or the 6MHW, QoL, and NYHA functional class, respec-
ively. The improvement in 6MHW distance seen in InSync
II patients continued even after adjusting for differences in
aseline 6MHW, age, beta-blocker use, QRS duration,
ender, and LV end-diastolic diameter between the two
roups (p  0.0016).
An analysis of changes in stroke volume during sequential
RT and several baseline characteristics (Table 6) identified
atients with a history of myocardial infarction as the only
ubgroup experiencing statistically significant improvement
n stroke volume (p  0.03) during optimal versus nominal
-V setting. The improvement in stroke volume at the
ptimal V-V interval continued throughout all follow-up
ntervals (PHD, three, and six months). Increase in stroke
olume in NYHA functional class IV patients with an
ptimized V-V setting was not statistically significant (p 
.1344), yet it was consistent across all follow-up intervals
PHD, three, and six months).
At the time of database closure on March 7, 2003, 65
atients had died. The classification scheme labeled 47 as
ardiac related and 18 as noncardiac. Arrhythmia accounted
or 26, and HF for 18 of the cardiac-related deaths. One
atient died from an acute myocardial infarction, one due to
n electrolyte imbalance from diuretic misuse, and one due
o drug-induced hypotension. The events committee clas-
ified one arrhythmic death as possibly procedure- or
evice-related.
ISCUSSION
ntil recently, commercially available CRT devices delivered
nly simultaneous Bi-V stimulation. Although simultaneous
nc III Implant Attempts and Follow-Up
ts Percentage 6 Months Percentage
1.2% 17 4.3%
0.9% 4 1.0%
0.2% 2 0.5%
1.9% N/A —
0.5% 7 1.8%
0.7% N/A —
0.7% N/A —
0.2% N/A —
0.7% N/A —
— 4 1.0%
2.6% 4 1.0%
8.8% 36 9.1%
ection or perforation, diaphragmatic/muscle stimulation,
palpitations; †Includes acidosis (1), acute renal failure (1),
ehydration (1), hypovolemia (1), nausea (1), paroxysymal
icardial effusion (1), pulmonary embolism (1), respiratory
lar accident (1); ‡patients could have experienced more than
 right atrial; RV  right ventricular; VF  ventricularInSy
temp
n diss
k, and
(1), d
1), per
rovascui-V CRT reduces patient symptoms and improves ventric-
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Efficacy of Sequential CRT December 20, 2005:2298–304lar function, exercise capacity, and QoL in patients with
oderate-to-severe HF and V-V conduction delays (5–13),
bout 30% of patients still do not respond to this therapy
20).
The ability to change the ventricular activation sequence
ight better overcome intrinsic conduction delay, improve
ardiac performance, and increase the likelihood of a clinical
esponse (20). Several small, short-term studies of sequen-
ial Bi-V pacing using various V-V intervals have shown
mproved hemodynamic performance (14–17). Whether
equential Bi-V CRT produces demonstrable clinical ben-
igure 1. Median changes in 6-min hall walk (A), quality of life score (B),
nd changes in New York Heart Association functional class (C) after six
onths. Black bars  improved two or more; diagonally lined bars 
mproved; white bars  no change; dotted bars  worsened. M 
ulticenter InSync Randomized Clinical Evaluation (MIRACLE) trial;
-CRT  MIRACLE Cardiac Resynchronization Therapy trial.fits remains undetermined.
*We evaluated the overall clinical effectiveness of sequen-
ial Bi-V pacing in a large cohort of NYHA functional class
II and IV HF patients in whom CRT was indicated. This
pproach significantly improves NYHA functional class, QoL,
nd 6MHW distance compared to control patients from
IRACLE who received conventional medical therapy
lone. Varying the V-V interval with echocardiographic guid-
nce incrementally increased stroke volume in the majority of
nSync III patients. One-half of the sequentially paced
atients experienced at least a 10% increase in stroke volume
t six months, while 14% of patients demonstrated a 20%
mprovement in stroke volume at six months. In 75% of the
nSync III patients, the optimal V-V interval was within a
elatively narrow range of 40 ms (stimulating the RV 40
s before the LV) to 40 ms (stimulating the LV 40 ms
efore the RV). Stimulating the LV before the RV most
ften yielded optimal stroke volume. The proportions of
atients with LV first, nominal, and RV first remained
table over time.
Sequential Bi-V CRT might improve ventricular stroke
olume by compensating for less than optimal LV lead
osition, by tailoring ventricular timing to correct for
ndividual heterogeneous ventricular activation patterns
ommonly found in patients with LV dysfunction and HF
14), or by overcoming regional conduction abnormalities
cross infarcted myocardium. Indeed, sequential Bi-V CRT
mproved stroke volume preferentially in InSync III patients
ith previous myocardial infarction, suggesting that the
bility to vary V-V timing may have compensated for
nfarct-related conduction block. However, the InSync III
tudy protocol did not systematically assign lead positions at
ifferent segments along the LV; thus, we cannot offer a
omprehensive analysis of whether sequential V-V activa-
ion compensates for seemingly suboptimal lead position.
Clinically, sequential Bi-V pacing provided mixed results.
nSync III patients did not demonstrate significantly greater
able 3. Percentage Improvement in Stroke Volume*
Visit n
% Patients
Improved Median Range
95%
LCB
rehospital
discharge
376 77.1% 8.6% 0%–93.5% 7.7%
hree-month 344 79.9% 8.4% 0%–69.6% 7.6%
ix-month 338 80.8% 7.3% 0%–58.7% 6.3%
Results shown are based on all patients with interventricular timing assessments
erformed according to protocol.
LCB  lower confidence bound.
able 4. Percent Improvement in Stroke Volume for the Subset
f Patients With Maximum Stroke Volume at a V-V Delay
ther Than Nominal
Follow-Up
Visit n Median p Value* Range
95%
LCB
rehospital
discharge
290 11.3% 0.009 0.5%–93.5% 10.2%
hree months 275 10.4% 0.114 0.3%–69.6% 9.7%
ix months 273 9.8% 0.548 0.4%–58.7% 8.3%Test for percentage improvement in stroke volume 10% (sign test).
LCB  lower confidence bound; V-V  interventricular.
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December 20, 2005:2298–304 Efficacy of Sequential CRTmprovement in NYHA functional class or QoL when
ompared to patients who received simultaneous Bi-V
acing in the MIRACLE study. InSync III patients did
xperience a significant improvement in exercise capacity,
emonstrating a median change in the 6MHW distance
0% greater (53 vs. 37.9 m) than that of the MIRACLE
atients receiving simultaneous Bi-V CRT. However, post-
oc analysis failed to show a correlation between improve-
ent in stroke volume and improved exercise capacity in the
nSync III patients (Spearman correlation analysis between
he changes in stroke volume and changes in 6MHW
howed that the correlation coefficient was0.0868 at three
onths and 0.0473 at six months. The p values were
.1132 and 0.3977, respectively). Using the improvement in
YHA functional class as an indicator of a positive response
o CRT, the response to sequential CRT in InSync III did
ot differ from the response to simultaneous CRT in
IRACLE. Furthermore, the differences in study design
rohibit drawing any meaningful clinical explanations in the
ifferences in these outcomes.
tudy limitations. Comparing the effects of sequential
i-V CRT to the control arm from the MIRACLE study
nd using the simultaneous Bi-V CRT arm of MIRACLE
gainst which to test the clinical effects of incremental
igure 2. Optimal interventricular timing settings at prehospital discharge,
hree, and six months. Diagonally lined bars  prehospital discharge;
lack bars  three months; white bars  six months.
able 5. Comparison of Change From Baseline to Six Months
f InSync III and MIRACLE Treatment Groups on Patient
utcomes
InSync III
MIRACLE
CRT p Value*
-min hall walk (n  340) (n  216)
Median 53.0 37.9 0.0001
Range 314.0 to 613.0 437.0 to 248.8
uality-of-life score (n  355) (n  216)
Median 19.0 16.0 0.1126
Range 91.0 to 29.0 88.0 to 47.0
YHA functional
class
(n  359) (n  215)
Median 1.0 1.0 0.3827
Range 3.0 to 1.0 3.0 to 1.0u
p values were calculated from two-sample t tests.
CRT  cardiac resynchronization therapy; other abbreviations as in Table 1.mprovements in stroke volume limit the comparison of
fficacy in this open-label evaluation of sequential CRT.
owever, the patient baseline characteristics, the investiga-
ive centers, and the overall study inclusions and end points
n the InSync III clinical study closely resemble those of
IRACLE. Furthermore, any baseline differences in
MHW, age, beta-blocker use, QRS duration, gender, and
V end-diastolic diameter did not confound the results of
he InSync III study.
The InSync III protocol measured LV stroke volume
able 6. Comparison of Stroke Volume Improvement Among
nSync III Subgroups
Characteristics
InSync III
394 Patients
Median % SV
Improvement
p
Value*
ender
Male 232 (58.9%) 8.1% 0.5099
Female 162 (41.1%) 7.9%
ge (yrs)
65 165 (41.9%) 7.9% 0.5980
65 229 (58.1%) 8.2%
jection fraction (%)
20 222 (56.4%) 7.8% 0.4471
20 172 (43.7%) 8.5%
YHA functional class
III 358 (90.9%) 7.9% 0.1344
IV 36 (9.1%) 10.1%
RS duration (ms)
160 140 (35.5%) 8.3% 0.5926
160 254 (64.5%) 7.9%
VEDD (mm)
70 228 (57.9%) 8.5% 0.1728
70 166 (42.1%) 7.6%
F etiology
Ischemic 186 (47.2%) 8.3% 0.3786
Nonischemic 208 (52.8%) 7.9%
yocardial infarction
Yes 139 (35.3%) 8.9% 0.0322
No 255 (64.7%) 7.7%
eta-blocker use
Yes 275 (69.8%) 7.9% 0.2868
No 119 (30.2%) 8.6%
trial rhythm history
History of atrial
arrhythmia
40 (10.1%) 8.1% 0.7240
Normal sinus
rhythm
354 (89.9%) 8.1%
entricular rhythm
history
History of
ventricular
arrhythmia
85 (21.6%) 7.2% 0.4983
Normal sinus
rhythm
309 (78.4%) 8.2%
rior surgery
Yes 160 (40.6%) 8.0% 0.5381
No 234 (59.4%) 8.1%
eft bundle branch
block
Yes 333 (84.5%) 8.0% 0.0978
No 61 (15.5%) 8.3%
alues are n (%). *The p values were calculated from the Wilcoxon rank-sum test.
HF  heart failure; LVEDD  left ventricular end-diastolic diameter; NYHA 
ew York Heart Association; SV  stroke volume.sing Doppler sampling at the aortic outflow. Small changes
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Efficacy of Sequential CRT December 20, 2005:2298–304n the angle of incidence between the outflow jet and the
ltrasound transducer or a small miscalculation of the
utflow tract dimension can introduce significant error into
he calculation of LV stroke volume. In an effort to maintain
onsistency in the echocardiography-Doppler methodology,
onographers underwent training, obtained measurements
t the same phase of the respiratory cycle, and selected the
-V stimulation sequence during testing in a random order
o reduce potential bias. The relative stability of the optimal
-V sequence during the six-month follow-up supports the
onsistency of the method used. No noninvasive assessment
f cardiac function has emerged as an ideal tool to analyze
he incremental changes in cardiac output produced by
trioventricular and V-V timing changes in ambulatory
atients. Clinical reports on digital plethysmography or chest
mpedance determination of aortic volume failed to identify a
ethod superior to the echocardiography-Doppler examina-
ion. Ongoing clinical trials of sequential Bi-V stimulation will
easure oxygen consumption at peak exercise to compare its
fficacy against simultaneous pacing. The adoption of other
nd points for analysis will help to further determine the
ncremental benefit of varying the V-V interval during CRT.
onclusions. Sequential Bi-V CRT with a V-V interval
ailored to each patient led to a modest increase in stroke
olume compared to simultaneous Bi-V CRT. Clinically,
ver the short-term, sequential Bi-V CRT led to greater
atient exercise capacity, but not fewer symptoms or im-
roved QoL when compared to patients receiving simulta-
eous Bi-V CRT. The likelihood of response appears similar;
owever, in certain individuals, optimization of the V-V delay
ay be useful in maximizing the response to CRT and
nhances the magnitude of response. Longer-term, random-
zed, controlled trials with objective end points will help
urther define the role of programmable V-V timing in
RT patient management.
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